ReviewJournal of clinical practice and research2026
Nanotechnology-Driven Strategies to Combat Antimicrobial Resistance in the One Health Era.
Review in Journal of clinical practice and research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antimicrobial resistance (AMR) has emerged as one of the greatest global public health threats, compromising the effectiveness of antibiotics and jeopardizing advances in modern medicine. The extensive use and misuse of antimicrobial agents in human medicine, veterinary practice, agriculture, and aquaculture have accelerated the emergence and spread of multidrug-resistant microorganisms. Because resistant pathogens, antibiotic residues, and resistance genes continuously circulate among humans, animals, and the environment, AMR is now recognized as a complex One Health challenge requiring coordinated, multidisciplinary solutions. However, conventional strategies, including the development of new antibiotics and antimicrobial stewardship programs, are increasingly constrained by rapid microbial adaptation, biofilm formation, delayed diagnosis, and the declining antibiotic discovery pipeline. Nanotechnology has emerged as a promising interdisciplinary platform capable of addressing several limitations of conventional antimicrobial approaches. Nanomaterials possess intrinsic broad-spectrum antimicrobial activity, enhance targeted drug delivery, improve biofilm eradication, and enable rapid pathogen detection through advanced nanodiagnostic systems. Furthermore, integrating nanotechnology with artificial intelligence, machine learning, and smart biosensing technologies is accelerating the development of precision antimicrobial therapies and real-time AMR surveillance systems. This review discusses the AMR crisis from a One Health perspective and summarizes recent advances in antimicrobial nanomaterials, nanodrug delivery systems, antibiofilm strategies, and nanodiagnostics. Current translational challenges and future perspectives are also highlighted, emphasizing the potential of nanotechnology to support sustainable AMR management across interconnected human, animal, and environmental sectors.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.